Vivos Therapeutics Inc. (VVOS)
Vivos Therapeutics Statistics
Share Statistics
Vivos Therapeutics has 5.89M shares outstanding. The number of shares has increased by 73.39% in one year.
| Shares Outstanding | 5.89M |
| Shares Change (YoY) | 73.39% |
| Shares Change (QoQ) | 21.8% |
| Owned by Institutions (%) | 0.33% |
| Shares Floating | 4.59M |
| Failed to Deliver (FTD) Shares | 991 |
| FTD / Avg. Volume | 0.84% |
Short Selling Information
The latest short interest is 220.59K, so 3.75% of the outstanding shares have been sold short.
| Short Interest | 220.59K |
| Short % of Shares Out | 3.75% |
| Short % of Float | 4.16% |
| Short Ratio (days to cover) | 2.34 |
Valuation Ratios
The PE ratio is -2.55 and the forward PE ratio is null. Vivos Therapeutics's PEG ratio is 0.03.
| PE Ratio | -2.55 |
| Forward PE | n/a |
| PS Ratio | 1.89 |
| Forward PS | 0.9 |
| PB Ratio | 3.57 |
| P/FCF Ratio | -2.24 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Vivos Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.5, with a Debt / Equity ratio of 0.19.
| Current Ratio | 1.5 |
| Quick Ratio | 1.5 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | -0.14 |
| Debt / FCF | -0.12 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $137.9K |
| Profits Per Employee | $-102.17K |
| Employee Count | 109 |
| Asset Turnover | 0.98 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 13.04% in the last 52 weeks. The beta is 7.28, so Vivos Therapeutics's price volatility has been higher than the market average.
| Beta | 7.28 |
| 52-Week Price Change | 13.04% |
| 50-Day Moving Average | 2.98 |
| 200-Day Moving Average | 3.23 |
| Relative Strength Index (RSI) | 55.05 |
| Average Volume (20 Days) | 118.35K |
Income Statement
In the last 12 months, Vivos Therapeutics had revenue of 15.03M and earned -11.14M in profits. Earnings per share was -1.68.
| Revenue | 15.03M |
| Gross Profit | 9.02M |
| Operating Income | -11.17M |
| Net Income | -11.14M |
| EBITDA | -10.59M |
| EBIT | -11.17M |
| Earnings Per Share (EPS) | -1.68 |
Balance Sheet
The company has 6.26M in cash and 1.51M in debt, giving a net cash position of 4.75M.
| Cash & Cash Equivalents | 6.26M |
| Total Debt | 1.51M |
| Net Cash | 4.75M |
| Retained Earnings | -104.19M |
| Total Assets | 15.28M |
| Working Capital | 2.5M |
Cash Flow
In the last 12 months, operating cash flow was -12.69M and capital expenditures 0, giving a free cash flow of -12.69M.
| Operating Cash Flow | -12.69M |
| Capital Expenditures | 0 |
| Free Cash Flow | -12.69M |
| FCF Per Share | -1.92 |
Margins
Gross margin is 60%, with operating and profit margins of -74.32% and -74.09%.
| Gross Margin | 60% |
| Operating Margin | -74.32% |
| Pretax Margin | -74.09% |
| Profit Margin | -74.09% |
| EBITDA Margin | -70.45% |
| EBIT Margin | -74.32% |
| FCF Margin | -84.43% |
Dividends & Yields
VVOS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for VVOS is $6.1, which is 113.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.1 |
| Price Target Difference | 113.3% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Oct 27, 2023. It was a backward split with a ratio of 1:25.
| Last Split Date | Oct 27, 2023 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -9.5 |
| Piotroski F-Score | 2 |